Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and Epitalon — mechanism, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved and not included in any major Western clinical guideline.
BPC-157
Epitalon
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
Epitalon
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
Epitalon
87
COAs
99.3%
Avg purity
14
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Epitalon remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
The evidence base is dominated by the Khavinson group. A 2003 paper in Bulletin of Experimental Biology and Medicine (Khavinson, Bondarev, Butyugov; PMID 12937682) reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. Additional Khavinson-group papers and reviews (e.g. 'Peptides and Ageing,' PMID 12374906) describe melatonin-rhythm normalization and claimed geroprotective effects in elderly Russian patients treated with epithalamin or epitalon in open-label / small-cohort studies over 6–12 year follow-up. These clinical studies have significant methodological limitations (open-label design, single-center, limited controls) and have NOT been independently replicated in rigorous Western controlled trials. There are no Phase 2/3 trials, no FDA approval, and no inclusion in Western clinical guidelines. Grey-market dosing of 5–10 mg SubQ daily for 10–20 day cycles, 1–2 times per year, is not clinically validated for any endpoint.
BPC-157 (Recovery) and Epitalon (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs